Background Repurposing broad-spectrum antivirals is an immediate treatment opportunity
for 2019 coronavirus disease (COVID-19). Favipiravir is an antiviral previously indicated for …

Background Favipiravir possesses high utility for treating patients with COVID-19. However,
research examining the efficacy and safety of favipiravir for patients with COVID-19 is …

The novel coronavirus outbreak began in late December 2019 and rapidly spread
worldwide, critically impacting public health systems. A number of already approved and …

Objectives This study aimed to evaluate the efficacy and adverse events of favipiravir in
patients with COVID-19. Methods Our protocol was registered on PROSPERO …

Background Favipiravir, an oral, RNA-dependent RNA polymerase inhibitor, has in vitro
activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite …

Favipiravir is a broad-spectrum oral antiviral agent that shows in vitro activity against SARS-
CoV-2. Presently, data on the real-world effectiveness and optimal dosage of favipiravir for …

Abstract The coronavirus disease-2019 (COVID-19) outbreak all over the world has led the
researchers to strive to develop drugs or vaccines to prevent or halt the progression of this …

Introduction At this time, there is no specific therapeutic or vaccine for treatment of the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Hence, available drugs for …

An outbreak of 2019‐nCoV infection has spread across the world. No specific antiviral drugs
have been approved for the treatment of COVID‐2019. In addition to the recommended …

Background Despite vaccination, many remain vulnerable to coronavirus disease 2019
(COVID-19) and its complications. Oral antivirals to prevent COVID-19 progression are vital …